// App-Quantinova.ai

: Recurrent Venous Thromboembolism (VTE), Major Bleeding (MB), and Associated Cost of Treatment with Low Molecular Weight Heparin (LMWH) or Direct Oral Anticoagulant (DOAC) in High Risk Patients with Gastrointestinal (GI) Malignancies: Retrospective Real-World Analysis at a Comprehensive Cancer Center

Researchers

Presenter

  • Alejandro Recio Boiles

Principal Investigators

  • Ali McBride

  • Hani M. Babiker

  • Nimer Alsaid

  • Ivo Abraham

  • Emad Elquza

Medical Centers

  • Division of Hematology-Oncology, Department of Medicine, University of Arizona Cancer Center, Tucson, AZ

  • Division of Hematology-Oncology, Department of Medicine, University of Arizona Cancer Center, Tucson, AZ

  • Gastrointestinal Cancer Program, Division of Hematology/Oncology, Department of Medicine, The University of Arizona Cancer Center, Tucson, AZ

  • Center for Health Outcomes and PharmacoEconomic Research, Department of Pharmacy, The University of Arizona Cancer Center, Tucson, AZ

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

  • Cardiovascular (CVS)

Disease

  • Venous thrombosis

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Heparin

Outcome

  • N/A

Study Design

  • Multinational

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved